References
- Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. doi:https://doi.org/10.1016/S0140-6736(20)30183-5.
- Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, et al. China novel coronavirus investigating and research team. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–33. doi:https://doi.org/10.1056/NEJMoa2001017.
- Gorbalenya AE, Baker SC, Baric RS, de Groot RJ, Drosten C, Gulyaeva AA, Haagmans BL, Lauber C, Leontovich AM, Neuman BW, et al. Severe acute respiratory syndrome-related coronavirus: the species and its viruses – a statement of the Coronavirus Study Group. Nat Microbiol. 2020;5:536–544. doi:https://doi.org/10.1038/s41564-020-0695-z.
- WHO. WHO statement regarding cluster of pneumonia cases in Wuhan, China. Beijing. WHO; 2020a Jan 9 [accessed 2020 Jan 11]. https://www.who.int/china/news/detail/09-01-2020-who-statement-regarding-cluster-ofpneumonia-cases-in-wuhan-china.
- WMHC. Wuhan Municipal Health Commission. Report of clustering pneumonia of unknown etiology in Wuhan City. 2019 [accessed 2020 Jan 14]. (http://wjw.wuhan.gov.cn/front/web/showDetail/2019123108989. opens in new tab).
- China CDC 2020. Chinese Center for Disease Control and Prevention. The 2019-nCoV Outbreak Joint Field Epidemiology Investigation Team, Li Q. Notes from the field: an outbreak of NCIP (2019-nCoV) infection in China — wuhan, Hubei Province, 2019-2020. China CDC Weekly. 2020;2:79–80.
- NHC. National Health Commission of the People’s Republic of China. Epidemic Prevention and Control of Dynamic; 2020 [accessed 2020 Mar 29]. http://www.nhc.gov.cn/xcs/yqtb/202002/ac1e98495cb04d36b0d0a4e1e7fab545.shtml.
- CDC. Center for disease control and prevention. 2020a [accessed 2020 Mar 25]. https://www.cdc.gov/coronavirus/2019-ncov/index.html.
- Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, Xing F, Liu J, Yip CC, Poon RW, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020;395(10223):514–23. doi:https://doi.org/10.1016/S0140-6736(20)30154-9.
- Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, Ren R, Leung KSM, Lau EHY, Wong JY, et al. Early transmission dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med. 2020;382(13):1199–207. doi:https://doi.org/10.1056/NEJMoa2001316.
- Chan JF, Kok KH, Zhu Z, Chu H, To KK, Yuan S, Yuen KY. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect. 2020;9(1):221–36. doi:https://doi.org/10.1080/22221751.2020.1719902.
- Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, Wang W, Song H, Huang B, Zhu N, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224):565–74. doi:https://doi.org/10.1016/S0140-6736(20)30251-8.
- Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, Hu Y, Tao ZW, Tian JH, Pei YY, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579(7798):265–69. doi:https://doi.org/10.1038/s41586-020-2008-3.
- Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, Si HR, Zhu Y, Li B, Huang CL, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270–73. doi:https://doi.org/10.1038/s41586-020-2012-7.
- Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–13. doi:https://doi.org/10.1016/S0140-6736(20)30211-7.
- Wu JT, Leung K, Leung GM. Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study. Lancet. 2020;395(10225):689–97. doi:https://doi.org/10.1016/S0140-6736(20)30260-9.
- Dhama K, Patel SK, Pathak M, Yatoo MI, Tiwari R, Malik YS, Singh R, Sah R, Rabaan AA, Bonilla-Aldana DK, et al. An update on SARS-COV-2/COVID-19 with particular reference on its clinical pathology, pathogenesis, immunopathology and mitigation strategies – a review. https://doi.org/Travel Med Inf Dis. 2020;101755. doi:https://doi.org/10.1016/j.tmain.2020.101755.
- Chen ZM, Fu JF, Shu Q, Chen YH, Hua CZ, Li FB, Lin R, Tang LF, Wang TL, Wang W, et al. Diagnosis and treatment recommendations for pediatric respiratory infection caused by the 2019 novel coronavirus. World J Pediatr. 2020;16(3):240–46. doi:https://doi.org/10.1007/s12519-020-00345-5.
- Ralph R, Lew J, Zeng T, Francis M, Xue B, Roux M, Toloue Ostadgavahi A, Rubino S, Dawe NJ, Al-Ahdal MN, et al. 2019-nCoV (Wuhan virus), a novel Coronavirus: human-to-human transmission, travel-related cases, and vaccine readiness. J Infect Dev Countr. 2020;14(1):3–17. doi:https://doi.org/10.3855/jidc.12425.
- CDC 2020b. Centers for disease control and prevention. Coronavirus Disease 2019 (COVID-19). Prevention & Treatment. 2020 [accessed 2020 Mar 15]. https://www.cdc.gov/coronavirus/2019-ncov/about/prevention-treatment.html.
- Lu H, Stratton CW, Tang YW. Outbreak of pneumonia of unknown etiology in Wuhan, China: the mystery and the miracle. J Med Virol. 2020;92(4):401–02. doi:https://doi.org/10.1002/jmv.25678.
- Paules CI, Marston HD, Fauci AS. Coronavirus infections-more than just the common cold. JAMA. 2020;323(8):707. doi:https://doi.org/10.1001/jama.2020.0757.
- WHO 2020b. World Health Organization Novel coronavirus – China. 2020 Jan 12 [accessed 2020 Jan 19]. http://www.who. int/csr/don/12-january-2020-novel-coronavirus-china/en/.
- Tian X, Li C, Huang A, Xia S, Lu S, Shi Z, Lu L, Jiang S, Yang Z, Wu Y, et al. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emerg Microbes Infect. 2020;9(1):382–85. doi:https://doi.org/10.1080/22221751.2020.1729069.
- Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, Graham BS, McLellan JS. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367(6483):1260–63. doi:https://doi.org/10.1126/science.abb2507.
- Shang W, Yang Y, Rao Y, Rao X. The outbreak of SARS-CoV-2 pneumonia calls for viral vaccines. NPJ Vaccines. 2020;5:18. doi:https://doi.org/10.1038/s41541-020-0170-0.
- Ahmed SF, Quadeer AA, McKay MR. Preliminary identification of potential vaccine targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV immunological studies. Viruses. 2020;12(3):E254. doi:https://doi.org/10.3390/v12030254.
- Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by the novel coronavirus from wuhan: an analysis based on decade-long structural studies of SARS coronavirus. J Virol. 2020;94(7):e00127–20. doi:https://doi.org/10.1128/JVI.00127-20.
- Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020;181(1):281–92. doi:https://doi.org/10.1016/j.cell.2020.02.058.
- Bassetti M, Vena A, Giacobbe DR. The novel Chinese coronavirus (2019-nCoV) infections: challenges for fighting the storm. Eur J Clin Invest. 2020;50(3):e13209. doi:https://doi.org/10.1111/eci.13209.
- Coutard B, Valle C, de Lamballerie X, Canard B, Seidah NG, Decroly E. The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. Antiviral Res. 2020;176:104742. doi:https://doi.org/10.1016/j.antiviral.2020.104742.
- Liu J, Zheng X, Tong Q, Li W, Wang B, Sutter K, Trilling M, Lu M, Dittmer U, Yang D. Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses SARS-CoV, MERS-CoV, and 2019-nCoV. J Med Virol. 2020;92(5):491–94. doi:https://doi.org/10.1002/jmv.25709.
- Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun. 2020;109:102433. doi:https://doi.org/10.1016/j.jaut.2020.102433.
- Dhama K, Sharun K, Tiwari R, Dadar M, Malik YS, Singh KP, Chaicumpa W. COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics. Hum Vaccin Immunother. 2020b:1–7. doi:https://doi.org/10.1080/21645515.2020.1735227.
- Dhama K, Sharun K, Tiwari R, Sircar S, Bhat S, Malik YS, Singh KP, Chaicumpa W, Bonilla-Aldana DK, Rodriguez-Morales AJ. Coronavirus disease 2019 – COVID-19. Preprints. 2020c;2020a:2020030001. doi:https://doi.org/10.20944/preprints202003.0001.v1.
- Malik YS, Sircar S, Bhat S, Sharun K, Dhama K, Dadar M, Tiwari R, Chaicumpa W. Emerging novel Coronavirus (2019-nCoV)-Current scenario, evolutionary perspective based on genome analysis and recent developments. Vet Q. 2020;40:68–76. doi:https://doi.org/10.1080/01652176.2020.1727993.
- Malik YS, Sircar S, Bhat S, Vinodhkumar OR, Tiwari R, Sah R, Rabaan AA, Rodriguez-Morales AJ, Dhama K. Emerging coronavirus disease (COVID-19), a pandemic public health emergency with animal linkages: current status update. Indian J Anim Sci. 2020;90(3):xx. doi:https://doi.org/10.20944/preprints202003.0343.v1.
- Casadevall A, Pirofski LA. The convalescent sera option for containing COVID-19. J Clin Invest. 2020:138003. doi:https://doi.org/10.1172/JCI138003.
- Pang J, Wang MX, Ang IYH, Tan SHX, Lewis RF, Chen JI, Gutierrez RA, Gwee SXW, Chua PEY, Yang Q, et al. Potential rapid diagnostics, vaccine and therapeutics for 2019 novel Coronavirus (2019-nCoV): A systematic review. J Clin Med. 2020;9(3):E623. doi:https://doi.org/10.3390/jcm9030623.
- Roback JD, Guarner J. Convalescent plasma to treat COVID-19: possibilities and challenges. JAMA. 2020;323(16):1561. doi:https://doi.org/10.1001/jama.2020.4940.
- Gurwitz D. Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. Drug Dev Res. 2020. doi:https://doi.org/10.1002/ddr.21656.
- Habibzadeh P, Stoneman EK. The novel Coronavirus: a bird’s eye view. Int J Occup Environ Med. 2020;11(2):65–71. doi:https://doi.org/10.15171/ijoem.2020.1921.
- Schoeman D, Fielding BC. Coronavirus envelope protein: current knowledge. Virol J. 2019;16(1):69. doi:https://doi.org/10.1186/s12985-019-1182-0.
- Gralinski LE, Menachery VD. Return of the Coronavirus: 2019-nCoV. Viruses. 2020;12(2):135. doi:https://doi.org/10.3390/v12020135.
- Letko M, Marzi A, Munster V. Functional assessment of cell entry and receptor usage for lineage B –coronavirus, including 2019-nCoV. Nat Microbiol. 2020. doi:https://doi.org/10.1038/s41564-020-0688-y.
- Morse JS, Lalonde T, Xu S, Liu WR. Learning from the past: possible urgent prevention and treatment options for severe acute respiratory infections caused by 2019-nCoV. Chembiochem. 2020;21(5):730–38. doi:https://doi.org/10.1002/cbic.202000047.
- Du L, He Y, Zhou Y, Liu S, Zheng BJ, Jiang S. The spike protein of SARS-CoV–a target for vaccine and therapeutic development. Nat Rev Microbiol. 2009;7(3):226–36. doi:https://doi.org/10.1038/nrmicro2090.
- Zhou Y, Jiang S, Du L. Prospects for a MERS-CoV spike vaccine. Expert Rev Vaccines. 2018;17(8):677–86. doi:https://doi.org/10.1080/14760584.2018.1506702.
- Hoffmann M, Kleine-Weber H, Kruger N, Muller M, Drosten C, Pohlmann S. The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular proteases TMPRSS2 for entry into target cells. bioRxiv. 2020. doi:https://doi.org/10.1101/2020.01.31.929042.
- Tetro JA. Is COVID-19 receiving ADE from other coronaviruses? Microbes Infect. 2020;22(2):72–73. doi:https://doi.org/10.1016/j.micinf.2020.02.006.
- Miller A, Reandelar MJ, Fasciglione K, Roumenova V, Li Y, Otazu GH. Correlation between universal BCG vaccination policy and reduced morbidity and mortality for COVID-19: an epidemiological study. medRxiv. 2020 Jan 1. doi:https://doi.org/10.1101/2020.03.24.20042937.
- Myint A, Jones T. Possible treatment of Covid-19 with a therapeutic vaccine. Vet Rec. 2020;186(13):419. doi:https://doi.org/10.1136/vr.m1302.
- Liu C, Zhou Q, Li Y, Garner LV, Watkins SP, Carter LJ, Smoot J, Gregg AC, Daniels AD, Jervey S, et al. Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases. ACS Cent Sci. 2020;6(3):315–31. doi:https://doi.org/10.1021/acscentsci.0c00272.
- Beigel JH, Voell J, Kumar P, Raviprakash K, Wu H, Jiao JA, Sullivan E, Luke T, Davey RT Jr. Safety and tolerability of a novel, polyclonal human anti-MERS coronavirus antibody produced from transchromosomic cattle: a phase 1 randomised, double-blind, single-dose-escalation study. Lancet Infect Dis. 2018;18(4):410–18. doi:https://doi.org/10.1016/S1473-3099(18)30002-1.
- WHO. Report of the WHO-China joint mission on Coronavirus Disease 2019 (COVID-19). 2020c. [accessed 2020 Mar 29]. Mission-on-covid-19-final-report.pdf. pp 1–40.
- WHO. Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected. 2020d [accessed 2020 Mar 15]. www.who.int/publications-detail/clinical-management-of-severeacute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected.
- Jin YH, Cai L, Cheng ZS, Cheng H, Deng T, Fan YP, Fang C, Huang D, Huang LQ, Huang Q; for the Zhongnan Hospital of Wuhan University Novel Coronavirus Management and Research Team, Evidence-Based Medicine Chapter of China International Exchange and Promotive Association for Medical and Health Care (CPAM), et al.. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Mil Med Res. 2020;7(1):4. doi:https://doi.org/10.1186/s40779-020-0233-6.
- Zhang Q, Wang Y, Qi C, Shen L, Li J. Clinical trial analysis of 2019-nCoV therapy registered in China. J Med Virol. 2020. doi:https://doi.org/10.1002/jmv.25733.
- Liu K, Fang YY, Deng Y, Liu W, Wang MF, Ma JP, Xiao W, Wang YN, Zhong MH, Li CH, et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chin Med J (Engl). 2020. doi:https://doi.org/10.1097/CM9.0000000000000744.
- Shanmugaraj B, Siriwattananon K, Wangkanont K, Phoolcharoen W. Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19). Asian Pac J Allergy Immunol. 2020a;38(1):10–18. doi:https://doi.org/10.12932/AP-200220-0773.
- Fu Y, Cheng Y, Wu Y. Understanding SARS-CoV-2-mediated inflammatory responses: from mechanisms to potential therapeutic tools. Virol Sin. 2020. doi:https://doi.org/10.1007/s12250-020-00207-4.
- Lu RM, Hwang YC, Liu IJ, Lee CC, Tsai HZ, Li HJ, Wu HC. Development of therapeutic antibodies for the treatment of diseases. J Biomed Sci. 2020;27(1):1. doi:https://doi.org/10.1186/s12929-019-0592-z.
- Liu L, Wei Q, Lin Q, Fang J, Wang H, Kwok H, Tang H, Nishiura K, Peng J, Tan Z, et al. Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection. JCI Insight. 2019;4(4):e123158. doi:https://doi.org/10.1172/jci.insight.123158.
- Zhang B, Zhou X, Zhu C, Feng F, Qiu Y, Feng J, Jia Q, Song Q, Zhu B, Wang J. Immune phenotyping based on neutrophil-to-lymphocyte ratio and IgG predicts disease severity and outcome for patients with COVID-19. medRxiv. 2020. doi:https://doi.org/10.1101/2020.03.12.20035048.
- Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, Wang X, Yuan J, Li T, Li J, et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clin Infect Dis. 2020. doi:https://doi.org/10.1093/cid/ciaa344.
- Pahl JH, Kwappenberg KM, Varypataki EM, Santos SJ, Kuijjer ML, Mohamed S, Wijnen JT, van Tol MJ, Cleton-Jansen AM, Egeler RM, et al. Macrophages inhibit human osteosarcoma cell growth after activation with the bacterial cell wall derivative liposomal muramyl tripeptide in combination with interferon-γ. J Exp Clin Cancer Res. 2014;33:27.
- Cao X. COVID-19: immunopathology and its implications for therapy. Nat Rev Immunol. 2020;20(5):269–70. doi:https://doi.org/10.1038/s41577-020-0308-3.
- Gao QY, Chen YX, Fang JY. Novel coronavirus infection and gastrointestinal tract. J Dig Dis. 2019:2020. doi:https://doi.org/10.1111/1751-2980.12851.
- Roper RL, Rehm KE. SARS vaccines: where are we? Expert Rev Vaccines. 2009;8(7):887–98. doi:https://doi.org/10.1586/erv.09.43.
- Graham RL, Donaldson EF, Baric RS. A decade after SARS: strategies for controlling emerging coronaviruses. Nat Rev Microbiol. 2013;11(12):836–48. doi:https://doi.org/10.1038/nrmicro3143.
- Shi SQ, Peng JP, Li YC, Qin C, Liang GD, Xu L, Yang Y, Wang JL, Sun QH. The expression of membrane protein augments the specific responses induced by SARS-CoV nucleocapsid DNA immunization. Mol Immunol. 2006;43(11):1791–98. doi:https://doi.org/10.1016/j.molimm.2005.11.005.
- Liu WJ, Zhao M, Liu K, Xu K, Wong G, Tan W, Gao GF. T-cell immunity of SARS-CoV: implications for vaccine development against MERS-CoV. Antiviral Res. 2017;137:82–92. doi:https://doi.org/10.1016/j.antiviral.2016.11.006.
- Ng OW, Chia A, Tan AT, Jadi RS, Leong HN, Bertoletti A, Tan YJ. Memory T cell responses targeting the SARS coronavirus persist up to 11 years post-infection. Vaccine. 2016;34(17):2008–14. doi:https://doi.org/10.1016/j.vaccine.2016.02.063.
- Ramaiah A, Arumugaswami V. Insights into cross-species evolution of novel human coronavirus 2019-nCoV and defining immune determinants for vaccine development. BioRxiv. 2020. doi:https://doi.org/10.1101/2020.01.29.925867.
- Bukreyev A, Lamirande EW, Buchholz UJ, Vogel LN, Elkins WR, St Claire M, Murphy BR, Subbarao K, Collins PL. Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS. Lancet. 2004;363(9427):2122–27. doi:https://doi.org/10.1016/S0140-6736(04)16501-X.
- Song Z, Xu Y, Bao L, Zhang L, Yu P, Qu Y, Zhu H, Zhao W, Han Y, Qin C. From SARS to MERS, thrusting coronaviruses into the spotlight. Viruses. 2019;11(1):59. doi:https://doi.org/10.3390/v11010059.
- Chen WH, Hotez PJ, Bottazzi ME. Potential for developing a SARS-CoV receptor-binding domain (RBD) recombinant protein as a heterologous human vaccine against coronavirus infectious disease (COVID)-19. Hum Vaccin Immunother. 2020:1–4. doi:https://doi.org/10.1080/21645515.2020.1740560.
- Ji H, Yan Y, Ding B, Guo W, Brunswick M, Niethammer A, SooHoo W, Smith R, Nahama A, Zhang Y. Novel decoy cellular vaccine strategy utilizing transgenic antigen-expressing cells as immune presenter and adjuvant in vaccine prototype against SARS-CoV-2 virus. Med Drug Discov. 2020;5:100026. doi:https://doi.org/10.1016/j.medidd.2020.100026.
- Shanmugaraj B, Malla A, Phoolcharoen W. Emergence of novel coronavirus 2019-nCoV: need for rapid vaccine and biologics development. Pathogens. 2020;9(2):E148. doi:https://doi.org/10.3390/pathogens9020148.
- Rosales-Mendoza S, Márquez-Escobar VA, González-Ortega O, Nieto-Gómez R, Arévalo-Villalobos JI. What does plant-based vaccine technology offer to the fight against COVID-19? Vaccines (Basel). 2020a;8(2):E183. doi:https://doi.org/10.3390/vaccines8020183.
- Rosales-Mendoza S. Will plant-made biopharmaceuticals play a role in the fight against COVID-19? Expert Opin Biol Ther. 2020b:1–4. doi:https://doi.org/10.1080/14712598.2020.1752177.
- Chen W, Wang Q, Li YQ, Yu HL, Xia YY, Zhang ML, Qin Y, Zhang T, Peng ZB, Zhang RC, et al. Early containment strategies and core measures for prevention and control of novel coronavirus pneumonia in China. Zhonghua Yu Fang Yi Xue Za Zhi. 2020;54(3):1–6. Chinese. doi:https://doi.org/10.3760/cma.j..0253-9624.2020.03.003.
- She J, Jiang J, Ye L, Hu L, Bai C, Song Y. 2019 novel coronavirus of pneumonia in Wuhan, China: emerging attack and management strategies. Clin Transl Med. 2020;9(1):19. doi:https://doi.org/10.1186/s40169-020-00271-z.
- Shen K, Yang Y, Wang T, Zhao D, Jiang Y, Jin R, Zheng Y, Xu B, Xie Z, Lin L, et al. China National Clinical Research Center for Respiratory Diseases; National Center for Children’s Health, Beijing, China; Group of Respirology, Chinese Pediatric Society, Chinese Medical Association; Chinese Medical Doctor Association Committee on Respirology Pediatrics; China Medicine Education Association Committee on Pediatrics; Chinese Research Hospital Association Committee on Pediatrics; Chinese Non-government Medical Institutions Association Committee on Pediatrics; China Association of Traditional Chinese Medicine, Committee on Children’s Health and Medicine Research; China News of Drug Information Association, Committee on Children’s Safety Medication; Global Pediatric Pulmonology Alliance. Diagnosis, treatment, and prevention of 2019 novel coronavirus infection in children: experts’ consensus statement. World J Pediatr. 2020. doi:https://doi.org/10.1007/s12519-020-00343-7.
- Tang HS, Yao ZQ, Wang WM. [Emergency management of prevention and control of novel coronavirus pneumonia in departments of stomatology]. Zhonghua Kou Qiang Yi Xue Za Zhi. 2020;55:E002.Chinese. doi:https://doi.org/10.3760/cma.j.cn112144-20200205-00037.
- Lu X, Xiang Y, Du H, Wing-Kin Wong G. SARS-CoV-2 infection in children - Understanding the immune responses and controlling the pandemic. Pediatr Allergy Immunol. 2020. doi:https://doi.org/10.1111/pai.13267.
- Ahn DG, Shin HJ, Kim MH, Lee S, Kim HS, Myoung J, Kim BT, Kim SJ. Current status of epidemiology, diagnosis, therapeutics, and vaccines for novel coronavirus disease 2019 (COVID-19). J Microbiol Biotechnol. 2020;30(3):313–24. doi:https://doi.org/10.4014/jmb.2003.03011.
- Genexine. hyFc platform. 2020 [accessed 2020 Apr 26]. http://www.genexine.com/m21.php.
- Seo YB, Im SJ, Namkoong H, Kim SW, Choi YW, Kang MC, Lim HS, Jin HT, Yang SH, Cho ML, et al. Crucial roles of interleukin-7 in the development of T follicular helper cells and in the induction of humoral immunity. J Virol. 2014;88(16):8998–9009. doi:https://doi.org/10.1128/JVI.00534-14.
- Sutter G, Fux R, Volz A, Song F, Becker S, Eickmann M. A novel vaccine against the Middle East Respiratory Syndrome coronavirus (MERS-CoV). 2016. EP3045181A1.
- Rao Z, Sheng F, Yang H, Cheng Y, Yan C, Yan W, He L, Shuang L, Yang X. Small-molecule inhibitor against MERS-CoV main protease, and preparation method and application thereof. 2016. CN105837487A.
- Kyratsous C, Stahl N, Sivapalasingam S. Human antibodies to Middle East respiratory syndrome - Coronavirus spike protein. 2019. US20190351049A1.
- Johnson RF, Schnell M, Hensley LE, Wirblich C, Coleman CM, Frieman MB. Multivalent vaccines for rabies virus and coronaviruses. 2017. WO2017176596A1.
- Jiang S. Don’t rush to deploy COVID-19 vaccines and drugs without sufficient safety guarantees. Nature. 2020;579(7799):321. doi:https://doi.org/10.1038/d41586-020-00751-9.
- Xiao Y, Torok ME. Taking the right measures to control COVID-19. Lancet Infect Dis. 2020;20(5):523–24. doi:https://doi.org/10.1016/S1473-3099(20)30152-3.
- Lu S. Timely development of vaccines against SARS-CoV-2. Emerg Microbes Infect. 2020;9(1):542–44. doi:https://doi.org/10.1080/22221751.2020.1737580.
- Thanh Le T, Andreadakis Z, Kumar A, Gómez RR, Tollefsen S, Saville M, Mayhew S. The COVID-19 vaccine development landscape. Nat Rev Drug Discov. 2020;19(5):305–06. doi:https://doi.org/10.1038/d41573-020-00073-5.